Clinical Trials Logo

Filter by:
NCT ID: NCT05745532 Recruiting - ß-thalassemia Clinical Trials

Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

Start date: December 1, 2020
Phase: Early Phase 1
Study type: Interventional

This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients

NCT ID: NCT05745363 Recruiting - Clinical trials for Differentiated Thyroid Cancer

Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer

Start date: February 24, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase Ib clinical trial to evaluate the efficacy and safety of AL2846 capsule in iodine-refractory differentiated thyroid cancer that has failed previous TKI treatment. The trial is planned to enroll 20 subjects. The trial is a single-arm, multi-center, open label clinical study. Objective response rate (ORR) is the primary endpoint.

NCT ID: NCT05745259 Recruiting - Clinical trials for Acute Ischemic Stroke

Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients (3T Stroke-Ⅲ)

Start date: October 26, 2022
Phase: Phase 3
Study type: Interventional

The trial is prospective, randomized, open-label, blinded endpoint (PROBE) design. Patients with acute ischemic stroke, who are eligible for standard intravenous thrombolysis within 4.5 hours of stroke onset will be randomized 1:1 to 0.25mg/kg or 0.9 mg/kg alteplase before all participants undergo endovascular thrombectomy.

NCT ID: NCT05745181 Recruiting - Clinical trials for Acute T-lymphoblastic Lymphoma

Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of anti-CD1a CAR-T in the treatment of relapsed refractory acute T-lymphoblastic leukemia/lymphoblastic lymphoma.

NCT ID: NCT05744687 Recruiting - Clinical trials for Locally Advanced or Metastatic Breast Cancer

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Start date: April 24, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer

NCT ID: NCT05744674 Recruiting - Clinical trials for Thoracoscopic Lobectomy

Phase Ⅱ Study of Intercostal Nerve Block With HR18034 for Postsurgical Pain Management

Start date: February 21, 2023
Phase: Phase 2
Study type: Interventional

Phase Ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection intercostal nerve block with HR18034 for postoperative pain management compared with ropivacaine.

NCT ID: NCT05744609 Completed - Pneumonia Clinical Trials

Predicting Severe Outcomes Among Children Hospitalized With Community-acquired Pneumonia

Start date: January 1, 2017
Phase:
Study type: Observational

In this study, investigators aimed to develop and validate a risk score to predict severe outcomes (e.g., mortality and ICU admission) in children who were admitted to the Children's Hospital of Fudan University between 2017 and 2022 due to community-acquired pneumonia (CAP). The objectives were as follows. 1. Develop a risk prediction model based on demographic, comorbidity, clinical characteristics, laboratory data, and chest radiographic reports to predict severe outcomes among children hospitalized with CAP; 2. Develop a risk scoring system and determine the cut-off point; 3. Externally validate the easy-to-use risk score.

NCT ID: NCT05744518 Recruiting - Breast Cancer Clinical Trials

Monitoring Response to Neoadjuvant Chemotherapy in Breast Cancer Using Ultrafast DCE-MRI

Start date: January 3, 2022
Phase:
Study type: Observational

The study will assess whether changes in kinetic parameters of tumor and peritumoral vasculature using ultrafast dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) during neoadjuvant chemotherapy (NAC) are predictive of pathologic complete response (pCR) in patients with breast cancer appropriate for NAC. pCR is defined as having no residual invasive breast cancer or ductal carcinoma in situ.

NCT ID: NCT05744505 Recruiting - Alopecia Areata Clinical Trials

1565nm Non-ablative Fractional Laser Treat Alopecia Areata

Start date: November 10, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate and explore the mechanism of 1565-nm non-ablative fractional laser in the treatment of alopecia areata. The main questions it aims to answer are: (a) comparing the secretion of various cells and cytokines around and within hair follicles before and after treatment; (b) determining the Lord Want effector cells with cytokines and demonstrating that they mediate involvement in correcting the immune immunity collapse process. Participants' 1/2 of the treated alopecia area was compared to their own other half of the untreated alopecia area, and they were followed every three months for efficacy assessment and scalp biopsy.

NCT ID: NCT05744440 Recruiting - Clinical trials for Acute Myeloid Leukemia

Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT

Start date: March 1, 2023
Phase: Early Phase 1
Study type: Interventional

This is an open label, single-arm, Phase I study to evaluate the efficacy and safety of allogenic natural killer(NK) cells in subjects with refractory or relapsed AML after allogeneic hematopoietic stem cell transplantation(allo-HSCT). A leukapheresis procedure will be performed to manufacture NK cells. Prior to allogenic NK cells infusion subjects will receive chemotherapy with azacitidine.